Home

CARB-X accelerates global antibacterial innovation by supporting the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our portfolio represents the world’s most scientifically diverse, early development pipeline of new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections.

396

$million

Invested

92

innovative

Projects

12

different

Countries

11

human clinical

TRIALS

2

available

DIAGNOSTICS

2

advanced development

FUNDING

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address drug-resistant bacterial infections.
Learn More


2020-2021

Annual Report

CARB-X closed its fifth fiscal year on July 31, 2021 with US$361 million awarded to 92 projects since inception

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Infectious Diseases Interventions, Wellcome Trust. Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

GHTC logo and Innovation award noticeProud recipient of the

2020 Innovating for Impact Partnership Award

from the Global Health Technologies Coalition (GHTC) 

Watch video

 

 

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Events

Events

10.04.22

 

ESCMID/ASM Conference on Drug Development

10.10.22

 

The Broken Pipeline of Antibiotics and Ongoing Efforts to Fix It

10.11.22

 

World Vaccine Congress | Europe

CARB-X News

  • 10.03.2022  |  CARB-X launches new funding rounds for critical global health needs full release

  • 07.08.2022  |  GARDP and CARB-X welcome renewed commitment by G7 leaders to address antimicrobial resistance full release

  • 06.16.2022  |  CARB-X expands international reach with appointment of Damiano de Felice as Director of Development and External Engagement full release

See All News

In The News

  • 09.20.2022  |  STD Experts Say US Faces Out of Control Syphilis and Gonorrhea Crisis full story

  • 09.13.2022  |  The five hottest private biotech companies in India full story

  • 09.13.2022  |  The superbugs are coming — oh wait, they’re here. full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.